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Abstract
Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing- remitting multiple sclerosis (RRMS)
and interferes with immune cell migration into the central nervous system by blocking the a4 subunit of very-late activation
antigen-4 (VLA-4). Although well tolerated and very effective, some patients still suffer from relapses in spite of natalizumab
therapy or from unwanted side effects like progressive multifocal leukoencephalopathy (PML). In search of a routine-
qualified biomarker on the effectiveness of natalizumab therapy we applied flow cytometry and analyzed natalizumab
binding to a4 and a4 integrin surface levels on T-cells, B-cells, natural killer (NK) cells, and NKT cells from 26 RRMS patients
under up to 72 weeks of therapy. Four-weekly infusions of natalizumab resulted in a significant and sustained increase of
lymphocyte-bound natalizumab (p,0.001) which was paralleled by a significant decrease in detectability of the a4 integrin
subunit on all lymphocyte subsets (p,0.001). We observed pronounced natalizumab accumulations on T and B cells at
single measurements in all patients who reported clinical disease activity (n=4). The natalizumab binding capacity of in vitro
saturated lymphocytes collected during therapy was strongly diminished compared to treatment-naive cells indicating a
therapy-induced reduction of a4. Summing up, this pilot study shows that flow cytometry is a useful method to monitor
natalizumab binding to lymphocytes from RRMS patients under therapy. Investigating natalizumab binding provides an
opportunity to evaluate the molecular level of effectiveness of natalizumab therapy in individual patients. In combination
with natalizumab saturation experiments, it possibly even provides a means of studying the feasability of patient-tailored
infusion intervals. A routine-qualified biomarker on the basis of individual natalizumab saturation on lymphocyte subsets
might be an effective tool to improve treatment safety.
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Introduction
Recruitment of activated immune cells across the blood-brain
barrier (BBB) into the central nervous system (CNS) is considered
essential for the initiation of inflammatory brain lesions in multiple
sclerosis (MS) [1,2]. Integrins are shown to be major players of
immune cell trafficking. The two most relevant interactions of
immune cell transmigration across the BBB involve firm adhesion
of the vascular cell adhesion molecule-1 (VCAM-1) on endothelial
cells with very late activation antigen-4 (VLA-4, a4b1 integrin) on
leukocytes and of the endothelial intercellular adhesion molecule-1
(ICAM-1) with leukocyte function associated antigen-1 (LFA-1,
aLb2 integrin) on immune cells [3,4]. The pathogenic relevance of
the a4b1 integrin was identified as early as 1992 by Yednock et al.
who demonstrated that CNS accumulations of leukocytes in
experimental autoimmune encephalomyelitis (EAE) are effectively
prevented by treatment with antibodies specific for the a4 subunit
[5].
Natalizumab was designed on the basis of mouse progenitor
antibodies by engineering complementarity-determining regions
onto a human IgG4 framework. In contrast to other IgG
subclasses, IgG4-antibodies are mere blocking antibodies with
minor affinity to immune cell Fc receptors, and they do not bind
complement. Hence, they are neither involved in antibody-
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31784dependent cell-mediated nor in complement-dependent cellular
cytotoxicity [6]. Natalizumab blocks immune cell extravasation
into the CNS by selectively binding to the a4 subunit of VLA-4
[7]. It is the first monoclonal antibody therapy approved for
treatment of MS and was shown to impressively reduce relapse
frequency and disease progression in patients with relapsing-
remitting MS (RRMS) [8,9]. However, the overall dimension of
the pharmacological activity of natalizumab is unsolved and
clinical effectiveness is counteracted by the risk to develop
progressive multifocal leukoencephalopathy (PML).
Current knowledge on further mechanisms of action include an
increaseofleukocytecounts,nucleatederythrocytes,pre-Bcells,and
CD34+ hematopoietic stem cells [10,8,11] in the peripheral blood,
reduced serum levels of soluble VCAM-1 [12], a sustained decrease
in immune cell numbers in the cerebrospinal fluid [13], and
depletion of dendritic cells in cerebral perivascular spaces [14].
Notably, the elevation of peripheral CD34+ cells and pre-B cells
might have pathogenic relevance for the development of PML since
the bone marrow was identified as reservoir of the JC virus [15,16].
According to the latest global natalizumab safety update 201 cases
of PML have been reported through Jannuary 4
th, 2012 (www.fda.
gov/Drugs/DrugSafety/ucm288186.htm). The risk of PML appar-
ently is time-dependent and the median therapy durationto onset of
PML symptoms was reported to be 25 months [17].
Occurrence of neutralizing anti-natalizumab antibodies (NAB)
is another important phenomenon influencing therapeutic effec-
tiveness. NAB have been detected in 9% of natalizumab-treated
patients from the AFFIRM study. Two thirds (6%) thereof
remained persistently NAB-positive and exhibited a reduced
clinical efficacy [18]. A more recent study reported persistent
NAB in 3.5% and non-persistent NAB in 1% of 4881 patients
suggesting lower frequencies of NAB [19].
Continuous efforts are required to early differentiate patients
with ongoing disease activity from patients with a solid treatment
response and to identify patients at risk to develop PML. Flow
cytometry might represent an appropriate method to investigate
individual treatment responsiveness by analyzing surface levels of
in vivo bound natalizumab.
Materials and Methods
Participants
Twenty-six patients (23 females, 3 males; mean age 35.1 years
69.3) with clinically definite RRMS according to the revised
McDonald criteria [20] were included in the study (Table 1). A
relapse was defined as acute or subacute onset of objective
symptoms of neurological disturbances that lasted for more than
24 hours and could be attributed to MS. Pseudoattacks were
excluded. Patients were recruited from the Department of
Neurology, Paracelsus Medical University, Salzburg, and received
natalizumab according to the European Medicines Agency’s
indication due to active disease despite previous immunomodu-
latory therapy. Steroid therapy less than one week ago and
ongoing infections were exclusion criteria for natalizumab
infusions. Patients received infusions of the standard 300 mg dose
of natalizumab every four weeks. Routine examinations for NAB
were performed before the second, third, and seventh natalizumab
infusion. Peripheral venous blood was collected before initiation of
natalizumab therapy (T0, n=26), after 12 weeks (T12, n=26), 24
weeks (T24, n=18), 36 weeks (T36, n=18), 48 weeks (T48,
n=18), and 72 weeks (T72, n=10) prior to subsequent infusions.
The study was approved by the local ethics committee
(Ethikkommission fu ¨r das Bundesland Salzburg 415-E774/6-
2007) and all participants gave written informed consent.
Sample preparation
Peripheral venous blood was collected in commercial peripheral
blood mononuclear cells (PBMC) enrichment tubes (Becton
Dickinson AG, Basel, Switzerland) and processed by centrifuga-
tion at 1800 g for 20 minutes. PBMC were washed twice in PBS,
resuspended in staining buffer (PBS pH 7.2, 2.5% fetal calf serum,
0.1% sodium acid) in a concentration of 1.2*10
6 lymphocytes/ml,
stained with saturating amounts of fluorescence-conjugated
monoclonal antibodies for 30 minutes on ice, and fixed with 1%
formaldehyde in PBS.
Flow cytometry
Natalizumab binding (anti-human IgG4 (a-huIgG4) [clone
HP6025, FITC]) and expression levels of the a4-integrin subunit
(anti-CD49d [clones HP2/1, FITC) were investigated on four
lymphocyte subpopulations (forward/sideward scatter, anti-CD3+
[clone UCHT1, ECD; identification of T cells], anti-CD19+
[clone J3-119, PC7; identification of B cells], and anti-CD16/56+
[clones 3G8 and N901, PE; identification of natural killer (NK,
CD32) and natural killer T (NKT, CD3+) cells]) by 5-color flow
cytometry (Cytomics FC500, Beckman Coulter, Vienna, Austria).
Isotype-matched antibodies (all IgG1) and anti-CD45+ [clone J33,
FITC, PE, ECD, PC7] antibodies were used as negative and
positive controls, respectively. With the exception of IgG1-FITC/
PE (Exalpha, Watertown, MA, USA) all antibodies were obtained
from Beckman Coulter, Vienna, Austria.
Relative fluorescence intensity (rfi) levels were calculated from
median fluorescence intensities (MFI) of all leukocyte subpopula-
tions as previously described [21,22]. In short, rfi levels were
calculated from the MFI by correcting them for the MFI of negative
controls (IgG1) and relating them to the MFI of positive controls for
a better inter- and intraindividual comparability. The calculation is
as follows: (MFI test sample2MFI isotype control)/(MFI positive
control2MFI isotype control)61000 (annotation: multiplication by
1000 in reference to the log scale). Anti-huIgG4 rfi levels will be
cited in the text as ‘‘anti-natalizumab rfi levels’’ and anti-CD49d rfi
levels will be cited in the text as ‘‘anti-a4 rfi levels’’.
Determination of NAB
Determination of neutralizing anti-natalizumab antibodies in
the serum was performed by ELISA at the Department of
Neurology, Innsbruck Medical University, Austria [12].
In vitro saturation of lymphocytes with natalizumab
Patient PBMC (1610
6 cells/ml) collected at baselines and after
12 weeks of natalizumab therapy were incubated with a final
concentration of 10 mg/ml natalizumab. Unbound natalizumab
was removed after 1 hour on ice by extensive washing. Staining
and flow cytometric analysis of a4 integrin levels (anti-CD49d-
FITC) and cell-surface bound natalizumab (anti-human IgG4-
FITC) on CD3+ T cells, CD19+ B cells, NK, and NKT cells were
performed as described above.
Statistical methods
For each cell type, a repeated measures ANOVA was applied to
analyze the means over time (T0, T12, T24, T36 and T48) for rfi
levels of anti-hulgG4-FITC (anti-natalizumab) and anti-a4-FITC.
Paired Fisher’s least significance difference tests were used as post-
hoc tests to compare means over time. To compare the cell types
against each other at a fixed time point, again repeated measures
ANOVA with paired Fisher’s least significance difference test as
post-hoc tests were applied. Whisker plots with 95% confidence
intervals for the means were used to illustrate the results.
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tion coefficients were performed with all cell types and done to
compare anti-huIgG4-FITC (anti-natalizumab) rfi levels from
natalizumab saturated cells collected at baseline or from cells
collected during natalizumab therapy with anti-a4-FITC rfi levels
from cells collected at baseline.
A p-value less than 5% indicates a statistically significant
difference or relation. All computations and illustrations were done
using Microsoft Excel (Microsoft Office 2007, Redmond, USA)
and STATISTICA 10 (Hill, T. & Lewicki, P. (2007). STATIS-
TICS: Methods and Applications. StatSoft, Tulsa, OK).
Results
Analysis of natalizumab binding to lymphocytes
This study comprises flow cytometric data from 26 RRMS
patients who cumulatively received 320 infusions and were on
1209.9 weeks of natalizumab therapy. In detail (Table 2), 10
patients on about 1.5 years of therapy (mean 75.0 weeks, range
67.9–82.1) received 19.060.5 infusions with a mean infusion
interval of 4.260.4 weeks. Eight patients on about 1 year of
natalizumab therapy (mean 50.6 weeks, range 44.2–56.2) received
12.861.3 infusions every 4.660.4 weeks and another 8 patients on
about 3 months of therapy (mean 12.0 weeks, range 9.2–14.8)
received mean 3.860.5 infusions every 4.560.5 weeks.
Natalizumab binding and surface availability of the a4 integrin
subunit on four lymphocyte subpopulations including CD3+ T
cells, CD19+ B cells, NK, and NKT cells were investigated. One
patient (#1) developed NAB and will be discussed separately
because results differed significantly.
Anti-natalizumab rfi levels on PBMC from 17 patients (#2–18)
were measured in 12 weeks intervals from baseline until up to 72
weeks of natalizumab therapy. After 12 weeks, we observed a
significant increase in mean anti-natalizumab rfi levels (p,0.001)
on all lymphocyte subsets compared to background levels obtained
at baseline. The increase was least in CD3+ T cells (1.860.5 fold)
and most pronounced in NK/NKT cells (2.760.9/0.8 fold)
(Figure 1A). Increases in anti-natalizumab rfi levels were
accompanied by a sharp decline of about 80% in mean a4 rfi
levels (p,0.001, Figure 1B). Both, the increase in anti-natalizumab
Table 1. Patient Characteristics - Clinical Parameters.
Age (y) During natalizumab Therapy Previous Therapies
ID Sex Onset
1 T0 Relapses
2 EDSS T0 Relapses
3 Last EDSS Duration (w) NAB
1 F 28 31 2 4.5 2 4.0 36 positive
4 22 mg IFN-ß-1a (s.c.), GA
2 F 28 29 4 0.0 0 1.0 48 negative 22 mg IFN-ß-1a (s.c.), 44 mg IFN-ß-1a (s.c.)
3 M 29 53 2 2.5 0 2.5 72 negative IVIG, IFN-ß-1b (s.c.)
4 F 18 24 2 0.0 0 0.0 48 negative 22 mg IFN-ß-1a (s.c.), 44 mg IFN-ß-1a (s.c.), IFN-ß-1a (i.m.), GA
5 F 21 25 6 1.0 0 1.0 72 negative 44 mg IFN-ß-1a (s.c.)
6 F 36 41 1 1.5 0 1.5 72 negative GA, 22 mg IFN-ß-1a (s.c.), 44 mg IFN-ß-1a (s.c.), Mitoxantrone
7 F 48 50 4 3.0 1 3.0 72 negative 22 mg IFN-ß-1a (s.c.), 44 mg IFN-ß-1a (s.c.)
8 F 23 33 4 3.0 0 2.5 48 negative 22 mg IFN-ß-1a (s.c.), 44 mg IFN-ß-1a (s.c.)
9 F 38 39 3 4.0 0 4.0 48 negative 22 mg IFN-ß-1a (s.c.), 44 mg IFN-ß-1a (s.c.)
10 F 33 35 2 3.0 2 4.5 72 negative 22 mg IFN-ß-1a (s.c.), 44 mg IFN-ß-1a (s.c.)
11 F 25 47 2 5.0 0 4.5 48 negative IFN-ß-1a (i.m.), GA
12 F 23 28 1 4.5 0 4.5 48 negative IFN-ß-1a (i.m.), 9.6 Mio/IU IFN-ß-1b (s.c.)
13 F 38 40 1 3.0 0 2.5 48 negative IFN-ß-1a (i.m.)
14 F 22 26 1 0.0 0 0.0 48 negative IFN-ß-1a (i.m.), GA, 9.6 Mio/IU IFN-ß-1b (s.c.)
15 F 27 35 4 4.5 1 4.0 48 negative 22 mg IFN-ß-1a (s.c.), IFN-ß-1a (i.m.)
16 F 25 26 2 7.0 1 7.0 48 negative IFN-ß-1a (i.m.)
17 F 25 34 4 3.5 0 3.5 48 negative 44 mg IFN-ß-1a (s.c.), GA
18 M 44 50 1 6.5 0 6.5 48 negative 44 mg IFN-ß-1a (s.c.), Mitoxantrone
19 F 25 38 3 2.0 0 2.0 12 negative 22 mg IFN-ß-1a (s.c.), GA
20 F 22 28 2 2.0 0 0.0 12 negative IFN-ß-1a (i.m.), GA
21 M 37 38 2 1.5 0 1.0 12 negative IFN-ß-1a (i.m.)
22 F 25 26 2 2.0 0 2.0 12 negative GA
23 F 40 51 2 4.0 0 4.0 12 negative 9.6 Mio/IU IFN-ß-1b (s.c.), GA
24 F 20 20 2 2.5 0 1.5 12 negative IFN-ß-1a (i.m.), GA, 9.6 Mio/IU IFN-ß-1b (s.c.)
25 F 22 26 2 0.0 0 0.0 12 negative 44 mg IFN-ß-1a (s.c.), GA
26 F 21 31 3 3.5 0 3.5 12 negative 44 mg IFN-ß-1a (s.c.)
Abbreviations: EDSS, Expanded Disability Status Scale; F, female; GA, glatiramer acetate; ID, identification number IFN-ß, Interferon-beta; i.m., intramuscularly; IU,
international units; M, male; NAB, natalizumab neutralizing antibodies; s.c., subcutaneously; T0, baseline; w, weeks; y, years.
1age at which first MS-specific symptoms were reported.
2number of relapses 12 months before natalizumab therapy.
3number of relapses during natalizumab therapy.
4non-persisting low titre NAB.
doi:10.1371/journal.pone.0031784.t001
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levels were stable from the week 12 through the week 72
measurements.
Anti-natalizumab rfi levels of PBMC from RRMS patients
collected at baseline were comparable to those of PBMC from
healthy controls and represent background signals (data not shown).
We found that natalizumab binding to NK cells and NKT cells
was significantly higher than natalizumab binding to CD3+ T cells
(p,0.001, both NK and NKT cells) and CD19+ B cells (p,0.001,
both NK and NKT cells). B cells had slightly higher anti-
natalizumab rfi levels than T cells. Natalizumab binding to NK
cells and NKT cells did not differ significantly (Figure 1A).
A potential unspecific adsorption of natalizumab to low-affinity
IgG Fc receptors (CD16) on NK cells was excluded by analyzing
natalizumab binding after in vitro treatment of cells with saturating
amounts of natalizumab in the presence and absence of Fc
receptor saturation reagent (data not shown).
Natalizumab therapy and the composition of lymphocyte
subsets
We examined relative frequencies of circulating lymphocytes
which showed significant and persistent increases of CD19+ B cells
(p,0.001) in patients on natalizumab therapy and expansions of
NK cells which were significant at weeks 36 (p,0.001), 48
(p,0.01), and 72 (p,0.01). Mean frequencies of the CD3+ T cell
population were significantly reduced (p,0.001) and mean
frequencies of NKT cells were largely unchanged (Table 3).
Single patients showed strongly deviating cell frequencies of NK
cells. At baseline, NK cell frequencies were between 6.9% to
14.3% in 15 patients but 21.3% and 22.1% in 2 patients (#10 and
#11). In contrast to the overall trend, NK cell frequencies of these
2 patients decreased. One of them (#10) reported disease activity.
Cell-bound Natalizumab and a4-integrin baseline levels –
two correlations by comparison
From the simple context that natalizumab blocks the a4-
integrin, a direct-proportional relation between lymphocyte
subset-specific differences in natalizumab binding and surface
expression of a4-integrin appeared conclusive. Accordingly, we
correlated anti-natalizumab rfi levels of lymphocytes collected at
weeks 12, 24, 36, and 48 (patients #2–18) with the anti-a4 levels of
natalizumab-naı ¨ve lymphocytes collected at baseline (Figure 2A).
Mean rfi levels of anti-natalizumab positively correlated with anti-
a4 baseline levels in NK (r=0.66, p=0.0038) and NKT cells
(r=0.58, p=0.015) but not with CD3+ T cells (r=20.13,
p=0.61) nor with CD19+ B cells (r=0.31, p=0.23).
This poor overall correlation was not expected. In a second
approach we used treatment-naive PBMC from 10 patients
collected at baseline and correlated anti-natalizumab rfi levels of
in vitro saturated lymphocytes with anti-a4 integrin levels of
natalizumab-naı ¨ve lymphocytes (Figure 2B). The results showed
highly significant and strongly positive correlations in all subsets:
CD3+ T cells (r=0.92, p=0.0001), CD19+ B cells (r=0.96,
p=0.00001), NK cells (r=0.93, p=0.00009), and NKT cells
(r=0.90, p=0.0004). Thus, the association of lymphocyte subset-
specific differences in a4-integrin expression levels and detectabil-
ity of natalizumab was established.
Natalizumab saturation and natalizumab binding
capacity
One possible explanation for the differing correlation results
between in vitro saturated lymphocytes collected at baseline and
lymphocytes with in vivo bound natalizumab collected during
therapy was, that latter lacked saturation. This led us to investigate
saturation levels of lymphocytes from patients under natalizumab
therapy. PBMC from 8 patients collected at baseline and at week
12 were in vitro treated with saturating amounts of natalizumab or
buffer and analyzed by flow cytometry. We found that additional
in vitro treatment with natalizumab only caused a minor increase of
anti-natalizumab rfi levels compared to therapy-derived in vivo
natalizumab levels which was 1.360.2 fold in case of CD3+ T
cells, and 1.260.1 fold for CD19+ B cells, NK cells, and NKT
cells. With the maximum natalizumab binding capacity of in vitro
saturated lymphocytes defined as 100% saturation, we showed
that lymphocytes collected at week 12 were approximately 80%
saturated (Figure 3A). Thus, we excluded lack of natalizumab as
cause for the poor correlation results. Next, we compared the
maximum natalizumab binding capacities of in vitro saturated
lymphocytes collected at baseline and in vitro saturated lympho-
cytes collected during therapy. We noticed significantly higher
anti-natalizumab rfi levels on in vitro saturated lymphocytes
collected at baseline compared to in vitro saturated lymphocytes
collected during therapy (p,0.01). The fold increase in anti-
natalizumab rfi levels in relation to background signals of
lymphocytes collected at baseline was 5.961.5 in CD3+ T cells,
5.661.5 in CD19+ B cells, 6.162.0 in NK cells, and 7.762.5 in
NK cells. This was 2–3 times the anti-natalizumab rfi values of in
vitro saturated cells collected under therapy. With anti-natalizumab
rfi levels of in vitro saturated lymphocytes collected at baseline
defined as 100% natalizumab binding capacity revealed a strongly
diminished natalizumab binding capacity of in vitro saturated
lymphocytes collected under therapy which was 58.9%619.1 in
NK cells, 49.2%610.0 in NKT cells, 46.2%621.1 in CD19+ B
cells, and 41.1%615.4 in CD3+ T cells (Figure 3B).
Apparently, lymphocytes collected during therapy have a
reduced capacity to bind natalizumab compared to treatment-
naive lymphocytes. A therapy-induced reduction in the maximum
natalizumab binding capacity of cells is a plausible explanation for
the poor correlation in figure 2A.
Table 2. Patient Characteristics - Means, Medians, and Standard Deviations of Treatment Parameters.




Patients mean (SD) median (SD) mean (SD) median (SD) mean (SD) median (SD)
72 weeks 10 19.0 (0.5) 19.0 (0.5) 75.0 (7.1) 77.1 (7.1) 4.2 (0.4) 4.3 (0.4)
48 weeks 8 12.8 (1.3) 13.0 (1.3) 50.6 (6.2) 52.3 (6.2) 4.6 (0.4) 4.4 (0.4)
12 weeks 8 3.8 (0.5) 4.0 (0.5) 12.0 (2.8) 12.4 (2.8) 4.5 (0.5) 4.2 (0.5)
Abbreviations: approx., approximately; SD, standard deviation.
doi:10.1371/journal.pone.0031784.t002
Lymphocyte-Bound Natalizumab and Flow Cytometry
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31784Natalizumab accumulations on lymphocytes from
individual patients
Figure 4 summarizes all measurements from patients #2–18
from baseline until week 48 in four charts, one for each
lymphocyte subset. Graphs #7, #10, #15 and #16 are bold
lines with identification marks and highlight the four patients who
reported disease activity during natalizumab therapy. The graphs
revealed pronounced inter- but also intra-individual differences in
natalizumab binding mainly as temporary increases (peaks). To
quantify these differences, rfi levels were translated into fold
increases by dividing anti-natalizumab rfi levels of the week 12, 24,
36, and 48 measurements by the anti-natalizumab background rfi
Figure 1. Flow cytometric analysis of natalizumab binding to four different lymphocyte subsets from RRMS patients under therapy.
Increase of anti-natalizumab rfi levels (A) and decrease of anti-a4 rfi levels (B) illustrated for CD3+ T cells (filled diamond), CD19+ B cells (open square),
NK cells (open triangle), and NKT cells (filled circle) at weeks 12 (T12, n=17), 24 (T24, n=17), 36 (T36, n=17), 48 (T48, n=17), and 72 (T72, n=10)
compared to background (anti-natalizumab) respectively baseline (anti-a4 rfi) levels (T0, n=17). Significance levels calculated for lymphocyte subset-
specific differences of anti-natalizumab rfi levels at each measurement during therapy are summarized in the associated table. Representative FACS
plots show anti-natalizumab rfi levels on CD3+ T cells at baseline, i.e. background signaling, (C) and after 12 weeks of natalizumab therapy (D). Anti-
natalizumab median fluorescence intensities of the above two FACS plots depicted as overlapping histrograms (E). ECD, electron coupled dye; FITC,
Fluorescein isothiocyanate; NK, natural killer cells; NKT, natural killer T cells; n.s., non significant; Rfi, relative fluorescence intensity; T(x), Time of
measurement (weeks); triple stars (***) highlight highly significant results (p,0.001); vertical bars represent 95% confidential intervals.
doi:10.1371/journal.pone.0031784.g001
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adding the mean fold increase in anti-natalizumab rfi levels of
weeks 12 to 48 from patients #2–18 and one standard deviation.
With this cut-off significant peaks of natalizumab accumulations
on lymphocytes were evaluated in the context of disease activity at
weeks 12, 24, 36, and 48 (Table 4).
Seven out of 17 patients had anti-natalizumab rfi levels above
cut-off at least once on CD3+ T cells, 8/17 on CD19+ B cells, 4/
17 on NK cells, and 6/17 on NKT cells. All four patients with
reported disease activity showed peaks in the CD3+ T (4/7) and
CD19+ B (4/8) lymphocyte subsets. In case of NK and NKT cells
only 1/4 and 2/6 were patients with reported disease activity.
Intraindividual differences in natalizumab binding either relate
to peaks at discrete measurements or to increased anti-natalizu-
mab rfi levels over minimum three time-points which are primarily
restricted to one lymphocyte subset. Patient #7, for example, had
pronounced anti-natalizumab rfi levels mainly on CD19+ B cells,
patient #5 on NK cells, patients #3 and #13 on NKT cells, and
patient #15 had them on CD3+ T cells, NK, and NKT cells.
Peaks in cell-bound natalizumab could not be associated with
higher a4 integrin baseline levels: the range of a4 baseline rfi levels
as defined by all patients was 21.2–34.6 on CD3+ T cells, 21.3–
54.3 on CD19+ B cells, 27.0–49.6 on NK cells, and 32.7–64.1 on
NKT cells. The baseline a4 rfi levels of patient #15, for example,
were within the patient-defined ranges (23.5 on T cells, 27.0 on
NK, and 43.1 on NKT cells). Similar was the case with a4 baseline
rfi levels on B cells from patient #7 (37.5), on NK cells from
patient #5 (39.5), and on NKT cells from patients #3 (58.9) and
#13 (46.5). These results illustrate that natalizumab accumula-
tions are not dependent on baseline a4 levels.
The case of a patient with non-persistent NAB
Flow cytometric analysis of immune cells from patient #1
revealed unaltered high a4 integrin levels and a lacking increase in
anti-natalizumab rfi levels at the week 12 measurement despite the
second and third infusions (Figure 5). This was highly suggestive of
NAB. In the course of ongoing treatment, a4 rfi levels declined and
natalizumab could be detected. PBMC collected shortly before the
seventh infusion showed an increase in anti-natalizumab rfi levels
of 15.3% on T cells, 14.8% on B cells, 53.4% on NK cells, and
59.8% on NKT cells compared to background levels. This
indicated that NAB were non-persistent. In routine laboratory
testing the presence of low titer NAB (sera collected at weeks 4 and
8) and their resolution (serum collected at week 24) were
confirmed. NAB were non-persistent, still, the patient suffered a
further relapse and natalizumab therapy was terminated after the
eighth infusion at week 28. Flow cytometric data collected 8 weeks
after the last infusion showed a slight recovery of a4 integrin levels,
but anti-natalizumab rfi levels were also still elevated on B cells
(+40.9%), NK cells (+90.1%), NKT cells (+133.8%), and to a lesser
extent on T cells (+29.3%). Twelve weeks after the last infusion
anti-natalizumab rfi levels were no longer above background levels
and a4 integrin rfi levels approached baseline levels again.
The B cell population showed a slight elevation from 4.1% at
baseline to 7.6% and 7.2% at the weeks 8 and 12 measurements
despite the presence of NAB. As soon as NAB resolved the B cell
population increased to 17.7% at week 24. Eight and twelve weeks
after the last infusion B cell numbers slowly declined along with
the wash-out of natalizumab to 14.0% and 8.4%, respectively.
Discussion
Natalizumab is a highly effective drug for the treatment of
RRMS [18]. The four-week intravenous application regimen
requires admittance to a medical center and facilitates exact
reports on the patients’ adherence to infusion intervals which is
important for molecular studies like this. Accordingly, mean and
median duration of therapy, numbers of infusions, and infusion
intervals have been assessed from all patients included in this
study. Our goal was to determine if serial analysis of natalizumab
binding to lymphocytes from RRMS patients by flow cytometry
has the potential to be applied as a biomarker for the individual
treatment response.
First, we determined that flow cytometry and the use of a
fluorescence-labeled monoclonal antibody specifically recognizing
the human IgG4 framework of natalizumab are appropriate to
investigate in vivo bound natalizumab on immune cells ex vivo.W e
show here that standard 300 mg natalizumab infusions induced a
significant increase of mean anti-natalizumab rfi levels on
lymphocytes compared to baseline which was most prominent
on NK and NKT cells (2.7 fold at the 12 weeks measurement) and
least pronounced in T cells (1.8 fold at the 12 weeks measurement).
The increase was consistent across the observation period until up
to 72 weeks of therapy. A concurrent sharp decline of
approximately 80% in mean a4 integrin levels confirmed
specificity of results because cell-bound natalizumab interfered
with attachment of our anti-a4 detection antibody (clone HP2/1).
Examination of the course of natalizumab binding to lympho-
cytes from individual patients, however, showed pronounced
intraindividual differences which appeared as natalizumab accu-
mulations at single measurements. To discriminate method-based
fluctuations from significant peaks a cut-off was determined using
mean anti-natalizumab rfi levels plus one standard deviation. With
this cut-off we singled out patients with strikingly high natalizumab
binding to one or more lymphocyte subsets and found this to be
Table 3. Changes in Frequencies of Lymphocyte Subsets during Natalizumab Therapy.
baseline 12 weeks 24 weeks 36 weeks 48 weeks 72 weeks
% (SD) % (SD) % (SD) % (SD) % (SD) % (SD)
CD3+ T cells 74.8 (6.2) 65.3 (5.9)*** 65.1 (5.3)*** 62.0 (8.2)*** 62.9 (5.2)*** 63,7 (6.0)***
CD19+ B cells 9.1 (3.5) 17.3 (6,6)*** 17.9 (6.3)*** 19.1 (8.0)*** 18.8 (6.7)*** 17.5 (3.8)***
NK cells 11.1 (4.7) 12.5 (3.7) 12.6 (4.6) 14.5 (4.3)*** 13.6 (3.5)** 14.4 (4.3)**
NKT cells 5.0 (2.7) 4.6 (2.7) 4.4 (2.5) 4.4 (2.4)* 4.7 (2.6) 4.,4 (2.7)
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31784Figure 2. Correlation results between cell-bound natalizumab and a4 integrin surface levels. (A) Anti-natalizumab rfi levels of week 12–48
measurements correlated with anti-a4 rfi levels from cells collected at baseline (n=17). Filled symbols highlight patients who reported disease
activity. (B) Anti-natalizumab rfi levels from in vitro saturated cells collected at baseline correlated with anti-a4 rfi levels from natalizumab-naı ¨ve cells
of the same blood collection (n=10). FITC, Fluorescein isothiocyanate; NatSat, in vitro treated cells with saturating amounts of natalizumab; NK,
natural killer cells; NKT, natural killer T cells; rfi, relative fluorescence intensity; T12–48, time of measurements at weeks 12–48.
doi:10.1371/journal.pone.0031784.g002
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25% of patients in NK and NKT cells. Excitingly, all of the four
patients with reported clinical disease activity had natalizumab
accumulations in T and B cells. This finding provides evidence
that flow cytometric analysis of natalizumab binding to T and B
lymphocytes actually deserves attention as a potential biomarker
for disease activity. The occurrence of natalizumab peaks in some
other patients fits perfectly to the fact that immunological or
MRI disease activities are only partly represented by clinical
manifestations.
The pivotal question certainly is - what are the underlying
mechanisms? An approach to this question requires knowledge on
natalizumab effects beyond the postulated blockade of the a4
integrin.
Natalizumab binding was most pronounced on NK and NKT
cells which suggested a higher a4 integrin surface expression on
these two lymphocyte subsets. We confirmed this by demonstrat-
ing a direct dependency and strong correlation between a4
integrin levels and the extent of natalizumab binding after in vitro
saturation on lymphocytes from untreated MS patients. Impor-
tantly, the positive correlation was lost in T cells and B cells when
comparing a4 integrin levels of treatment-naive cells collected at
baseline with natalizumab binding to lymphocytes collected after
12 weeks of therapy. And, the positive correlation was still existent
Figure 3. Maximum natalizumab binding capacity and natalizumab saturation before and during natalizumab therapy. (A) Percent
natalizumab saturation of T cells, B cells, NK cells, and NKT cells collected at week 12 (T12, n=8) during therapy related to maximum natalizumab
binding capacity of lymphocytes from the same blood collection after in vitro treatment with saturating amount of natalizumab (100%). (B) Percent
maximum natalizumab binding capacity of in vitro saturated T cells, B cells, NK cells, and NKT cells collected at week 12 (T12, n=8) related to
maximum natalizumab binding capacity of in vitro saturated lymphocytes from the same donors collected at baseline (100%). Vertical bars represent
95% confidential intervals. Max, maximum; NAT, natalizumab; NK, natural killer cells; NKT, natural killer T cells; T(x), time of measurement (weeks).
doi:10.1371/journal.pone.0031784.g003
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indicates that natalizumab therapy leads to altered a4 integrin
surface levels and that T and B cells apparently are more affected
than NK and NKT cells. This observation is in line with Niino et
al [24] who reported that natalizumab therapy induced a down-
regulation of a4 integrin expression on immune cells. In contrast to
us, they investigated a4 integrin levels using a detection antibody of
different epitope specificity than natalizumab. We were less
interested in the differential surface expressions of a4 integrin
but wanted to investigate the impact of natalizumab therapy on
the overall capacity of cells to bind natalizumab. Accordingly, we
analyzed the maximum natalizumab binding capacity after in vitro
saturation of lymphocytes from patients collected at baseline and
after three months of therapy. We found an impressive reduction
of about 40% (NK cells) to about 60% (T cells) in the maximum
natalizumab binding capacity of lymphocytes from patients on
therapy compared to lymphocytes from the same patients prior to
treatment. Again, T and B cells showed a more pronounced effect
and higher reduction in their natalizumab binding capacity than
the two other subsets.
These findings led us to suggest that natalizumab primarily
affects T and B cells via lower abundance in a4 integrin surface
levels. Specifically responsive to therapy, these cells also might be
exceptionally sensitive and reactive in the context of immune
activities evidenced as accumulations of natalizumab. The more so
as the antiviral cytokine interferon-alpha, for example, has been
shown to up-regulate surface expression of the a4 integrin on T
cells [25]. This could explain both that natalizumab peaks above
cut-off occurred in all patients with reported clinical disease
activity and that they were more frequent in T and B cells
compared to NK and NKT cells.
NK and NKT cells have considerably higher a4 integrin levels
than T and B cells, but the relevance is controversial. Higher a4
integrin levels on CD8+ T cells, for example, have been implicated
in the altered CD4+/CD8+ T cell ratio in the cerebrospinal fluid
of natalizumab-treated patients [26]. Others have shown that a4
integrin levels do not necessarily correlate with the adhesive
property of cells [27]. Generally, the role of NK and NKT cells in
the pathogenesis of MS is not resolved. NK cells have been
reported to exert a decreased cytotoxic activity during relapses
[28,29], to interfere with autoimmune responses by secreting anti-
inflammatory cytokines [30], and to be involved in the decrease of
relapse rates during pregnancy [31]. Moreover, NK cells have
been shown to expand in response to MS therapeutics, including
interferon-beta [32], the monoclonal antibody daclizumab [33],
and, very recently, also natalizumab [11]. We too, observed an
increase of NK cell numbers during natalizumab therapy in all but
two of our patients. Latter had striking high NK cell frequencies at
baseline which actually decrease in the course of therapy.
Natalizumab apparently exerts differential effects on NK cell
subsets besides the supposed boosting of immune regulatory NK
cells. Future studies on NK cells classified as regulatory or
cytotoxic subsets, activators or inhibitors of target cell killing, will
provide substantial insights into the interactions between natali-
zumab and NK cells, and will possibly answer the question
whether natalizumab binding to NK cells rather interferes with
Figure 4. Individual courses of natalizumab binding during therapy. Anti-natalizumab rfi of each patient and measurement depicted for
CD3+ T cells (A), for CD19+ B cells (B), for NK cells(C), for NKT cells(D). Graphs of patients with reported disease activity are highlighted as bold lines
with open circles, squares, triangles, or diamonds as identification marks. FITC, Fluorescein isothiocyanate; NK, natural killer cells; NKT, natural killer T
cells; Rfi, relative fluorescence intensity; Tx, time of measurement (weeks).
doi:10.1371/journal.pone.0031784.g004
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genesis of MS.
A hot topic emerged from the major decrease in maximum
natalizumab binding capacity of lymphocytes during natalizumab
treatment. It involves the rationale for monthly applications of
300 mg natalizumab and the feasibility of patient-tailored infusion
intervals with regards to opportunistic side effects like PML. Early
safety and pharmacokinetic studies reported natalizumab serum
concentrations detectable until 3–8 weeks after a single 3 mg/kg
intravenous dose [34]. Elimination of biologics like monoclonal
antibodies is generally slow and involves proteolysis, renal
filtration, and intracellular catabolism after endocytosis [35].
Salvage from lysosomal degradation by Fc receptors of neonatal
(FcRn) and escape from immune-mediated elimination mecha-
nisms due to its IgG4 framework cause the extremely low systemic
clearance and prolonged terminal half-life of natalizumab [6,36].
Rispens et al [37] recently developed a sophisticated ELISA for
quantifying serum natalizumab and identified single patients with
exceptional high natalizumab levels four weeks post infusion. The
substantial differences in individual pharmacokinetics and the
reduced cellular natalizumab surface load during therapy add one
more indication for monitoring natalizumab binding to immune
cells by flow cytometry. The possibilities and procedures for
implementing patient-optimized infusion intervals should be
investigated in controlled studies.
Last, we discuss the issue of monitoring the occurrence of NAB
by flow cytometry. Despite the fact of an increase in allergic
reactions, Calabresi et al. [18] suggested not to test for NAB within
the first months of therapy to avoid uncertainties regarding
treatment continuation in case of positive results. Their indication
for NAB testing is restricted to identify patients with persistent
NAB which are associated with a continuing insufficient treatment
response. In contrast, Defer et al. [38] recently suggested to
investigate surface expression of the a4 integrin by flow cytometry
as a surrogate marker for treatment efficacy. In our patient
occurrence of NAB was clearly evidenced by lack of anti-
natalizumab rfi levels and unchanged baseline a4 rfi levels despite
repeated infusions. NAB were non-persistent as indicated by a
decline in a4 surface levels prior to the seventh infusion.
Nonetheless, the patient suffered a second relapse resulting in
the termination of natalizumab therapy. The patient showed a
very slow recovery of a4 levels which, on T cells, were not back at
baseline even 12 weeks after the last infusion.
A novel observation is that assessment of B cell frequencies
apparently functions as sensitive marker for residual natalizumab
activity which is not detected by flow cytometric analysis of a4
integrin or anti-natalizumab levels. B cell frequencies doubled with
start of therapy despite presence of NAB, quadruplicated upon
resolution of NAB, and were still twice the baseline levels at the
final measurement 12 weeks after the last infusion. Our case
reveals that repeated immune cell monitoring by flow cytometry is
feasible and indicative. It provides immediate information on
persistence or non-persistence of NAB which can be continuously
matched with clinical parameters and the patient’s condition. Such
Table 4. Evaluation of natalizumab accumulations on lymphocyte subsets from individual patients at single time-points.
CD3+ T cells CD19+ B cells NK cells NKT cells
ID T12/T0 T24/T0 T36/T0 T48/T0 T12/T0 T24/T0 T36/T0 T48/T0 T12/T0 T24/T0 T36/T0 T48/T0 T12/T0 T24/T0 T36/T0 T48/T0
2 1.65 1.37 1.28 1.37 1.60 1.43 1.10 0.95 2.56 2.23 1.86 2.02 2.16 1.92 2.17 2.02
3 1.79 1.92 1.47 2.52 2.12 2.26 1.91 3.48 2.94 2.80 2.92 3.78 3.88 3.88 2.37 4.52
4 3.37 2.22 1.61 2.46 3.24 2.40 1.90 2.14 4.09 3.03 2.49 2.77 3.36 2.56 2.26 3.22
5 2.57 2.05 1.76 1.81 3.03 2.67 2.10 2.15 4.55 3.62 3.06 3.55 3.37 2.57 2.37 2.42
6 1.53 1.63 1.76 2.20 1.55 1.62 1.74 2.20 2.66 2.51 2.64 3.17 2.43 2.55 2.47 2.90
7 2.27 2.85+ 2.01 3.03+ 3.04+ 4.12+ 3.25+ 4.40+ 2.94 2.93 2.36 3.24 2.69 4.23+ 1.70 2.57
8 1.29 1.45 1.16 1.40 1.45 2.00 1.39 1.40 1.76 1.91 1.58 1.49 1.80 2.44 2.09 2.19
9 1.75 2.08 1.89 1.24 2.35 2.44 1.89 1.14 1.92 2.75 1.70 1.26 2.09 3.19 2.64 2.00
10 1.55 1.47 2.48+ 1.82 1.52 1.36 2.80+ 1.67 1.97 1.80 2.86 2.25 1.86 1.77 2.49 1.90
11 1.46 1.31 1.44 1.11 1.14 1.29 1.50 1.05 1.75 1.68 1.70 1.63 2.23 1.78 1.78 1.75
12 1.34 1.62 1.47 1.72 1.02 1.33 1.36 1.61 3.15 2.72 2.87 2.48 2.23 3.75 3.90 4.21
13 1.93 1.89 1.97 1.70 1.99 1.68 2.28 1.74 1.89 1.74 2.20 1.70 4.31 4.50 4.99 4.08
14 1.61 1.52 1.43 1.51 2.51 1.62 1.74 1.69 3.28 2.53 2.56 2.28 2.65 2.20 2.20 2.11
15 2.26 2.58+ 2.51+ 2.90+ 1.66 2.17 2.38 3.43+ 3.61+ 4.37+ 4.20+ 4.79+ 3.56+ 3.93+ 4.27+ 3.53
16 2.11 1.68 1.58 2.74+ 1.67 1.64 1.07 3.16+ 2.12 2.07 1.73 2.81 3.44 3.17 2.82 3.73+
17 1.10 1.31 1.55 2.25 1.64 2.03 1.66 3.25 1.87 2.24 2.11 3.16 1.96 2.68 2.45 3.18
18 1.83 1.64 1.41 1.32 1.96 1.98 1.83 2.20 2.29 2.23 1.95 2.19 2.04 1.93 1.62 1.50
mean 1.82 2.02 2.56 2.76
SD 0.50 0.74 0.78 0.87
Cut-off
1 2.32 2.76 3.34 3.63
Abbreviations: ID, identification number; NK, natural killer cells; NKT, natural killer T cells; SD, standard deviation; T, time of measurement; Tx/T0, quotient of anti-
natalizumab rfi levels of measurements performed during natalizumab therapy (T12,…,48) and background rfi levels from measurements performed at baseline (T0);
Bold ID numbers highlight patients with reported disease activity; bold results highlight values above cut-off; bold results with plus signs highlight values above cut-off
of patients with reported disease activity.
1cut-off defined as sum of means plus one standard deviation.
doi:10.1371/journal.pone.0031784.t004
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from individual disease courses and provide a basis for more
precise case-to-case specific decisions for affected individuals.
Summing up, clinical effectiveness of natalizumab is tightly
linked to blocking the a4 integrin and can be easily investigated by
flow cytometry. In this study we observed significant accumula-
tions of natalizumab on patient lymphocytes that possibly signalize
immunologic disease activity. We found an expansion of NK cells
in most patients and a reduction in two individuals which could
indicate further unknown effects of natalizumab. We saw a strong
decrease in the natalizumab binding capacity of lymphocytes
during therapy which suggests a certain potential to customize
infusion intervals.
We concede that the small number of patients with relapse
activity and NAB presented in this pilot study only allow careful
interpretations. Nevertheless, investigating natalizumab binding to
lymphocytes adds important information for the clinician. Flow
cytometric analysis of cell-bound natalizumab appears promising
in the search for biomarkers for treatment effect and pending
relapse activity in individual cases. And, it might turn out the basis
for further studies on optimizing infusion intervals which would
greatly improve treatment safety.
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